SEC Form 4 · accession 0001437749-17-012379

Oxford Immunotec Global PLC · OXFD

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

Jul 5, 2017

Accepted (ET)

Jul 7, 2017 · 4:30 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001586049

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Ordinary Shares^F1	Jul 5, 2017	M	16,438	$0.81	A	478,106	D
Ordinary Shares^F3	Jul 5, 2017	S	16,438	$16.5822	D	461,668	D
Ordinary Shares^F1	Jul 5, 2017	M	16,394	$0.81	A	478,062	D
Ordinary Shares^F3	Jul 5, 2017	S	16,394	$16.5822	D	461,668	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F4	$0.81	Jul 5, 2017	M	16,438	D	—	Feb 17, 2020	Ordinary Shares	16,438	0	D
Stock Option (Right to Buy)^F5	$0.81	Jul 5, 2017	M	16,394	D	—	Dec 31, 2022	Ordinary Shares	16,394	176,441	D

F1The original exercise price of these options was priced in GBP at GBP0.51 and converted to US$ at an exchange rate of US$1.58823=1GBP.
F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2015, as amended.
F3The price reported for the sales on July 5, 2017 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.275 to $16.83 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
F4Exercise from an option granted February 28, 2013, which became fully vested on April 1, 2014.
F5Exercise from an option granted November 7, 2012, which became fully vested on December 31, 2016.